The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency-Reference-Cited by-同舟云学术

The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency

Published:2018 Issue:5 Volume:57 Page:701-706
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Iwadate Dosuke¹,Hasegawa Eiko¹,Hoshino Junichi¹,Hayami Noriko¹,Sumida Keiichi¹,Yamanouchi Masayuki¹,Sekine Akinari¹,Kawada Masahiro¹,Hiramatsu Rikako¹,Suwabe Tatsuya¹,Sawa Naoki¹,Yuasa Mitsuhiro²,Wake Atsushi²,Fujii Takeshi³,Ohashi Kenichi³⁴,Takaichi Kenmei¹⁵,Ubara Yoshifumi¹⁵

Affiliation:

1. Nephrology Center, Toranomon Hospital, Japan

2. Department of Hematology, Toranomon Hospital, Japan

3. Department of Pathology, Toranomon Hospital, Japan

4. Department of Pathology, Yokohama City University, Graduate School of Medicine, Japan

5. Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/57/5/57_9263-17/_pdf

Reference12 articles.

1. 1. Sipe JD, Benson MD, Buxbaum JN, et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21: 221-224, 2014.

2. 2. Gertz MA, Dispenzieri A. Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials. Oncology (Williston Park) 26: 152-161, 2012.

3. 3. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 387: 2641-2654, 2016.

4. 4. Perz JB, Schonland SO, Hundemer M, et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis:a single centre prospective phase II study. Br J Haematol 127: 543-551, 2004.

5. 5. Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 97: 1885-1887, 2001.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Digital whole‐slide imaging of changes in amyloid after peripheral blood stem cell transplantation in patients with amyloid light‐chain amyloidosis;Pathology International;2024-07-17

2. Prevalence, clinical characteristics and treatment outcome of factor X deficiency in a consecutive cohort of primary light-chain amyloidosis;LEUKEMIA RES;2022

3. Prevalence, clinical characteristics and treatment outcome of factor X deficiency in a consecutive cohort of primary light-chain amyloidosis;Leukemia Research;2022-09

4. Kidney biopsy guidebook 2020 in Japan;Clinical and Experimental Nephrology;2021-02-19

5. Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis;CEN Case Reports;2019-09-14